Sumitomo Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SUMITOMO PHARMA, and when can generic versions of SUMITOMO PHARMA drugs launch?
SUMITOMO PHARMA has four approved drugs.
There are forty-four US patents protecting SUMITOMO PHARMA drugs.
There are five hundred and thirty-six patent family members on SUMITOMO PHARMA drugs in forty-one countries and twenty-seven supplementary protection certificates in fifteen countries.
Summary for Sumitomo Pharma
| International Patents: | 536 |
| US Patents: | 44 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Sumitomo Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma | ORGOVYX | relugolix | TABLET;ORAL | 214621-001 | Dec 18, 2020 | RX | Yes | Yes | 10,449,191 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Sumitomo Pharma | ORGOVYX | relugolix | TABLET;ORAL | 214621-001 | Dec 18, 2020 | RX | Yes | Yes | 7,300,935 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-003 | May 21, 2020 | DISCN | Yes | No | 8,603,514 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-002 | Nov 8, 2013 | AB | RX | Yes | No | 9,206,135 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | DISCN | Yes | No | 9,283,219 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-001 | Nov 8, 2013 | AB | RX | Yes | No | 9,750,747 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sumitomo Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-002 | May 21, 2020 | 11,077,068 | ⤷ Try a Trial |
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-003 | May 21, 2020 | 8,765,167 | ⤷ Try a Trial |
| Sumitomo Pharma Am | LONHALA MAGNAIR KIT | glycopyrrolate | SOLUTION;INHALATION | 208437-001 | Dec 5, 2017 | 6,962,151 | ⤷ Try a Trial |
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | 8,765,167 | ⤷ Try a Trial |
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | 8,663,687 | ⤷ Try a Trial |
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-002 | May 21, 2020 | 8,663,687 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Sumitomo Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2019200138 | ⤷ Try a Trial |
| South Korea | 101890317 | ⤷ Try a Trial |
| Brazil | 112017018173 | ⤷ Try a Trial |
| European Patent Office | 1456702 | ⤷ Try a Trial |
| Colombia | 5590921 | ⤷ Try a Trial |
| Japan | 2018172407 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sumitomo Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0751129 | SPC/GB09/047 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ESLICARBAZEPINE ACETATE; REGISTERED: UK EU/1/09/514/001 20090421; UK EU/1/09/514/002 20090421; UK EU/1/09/514/003 20090421; UK EU/1/09/514/004 20090421; UK EU/1/09/514/005 20090421; UK EU/1/09/514/006 20090421; UK EU/1/09/514/019 20090421; UK EU/1/09/514/020 20090421; UK EU/1/09/514/013 20090421; UK EU/1/09/514/014 20090421; UK EU/1/09/514/015 20090421; UK EU/1/09/514/016 20090421; UK EU/1/09/514/017 20090421; UK EU/1/09/514/018 20090421; UK EU/1/09/514/007 20090421; UK EU/1/09/514/008 20090421; UK EU/1/09/514/009 20090421; UK EU/1/09/514/010 20090421; UK EU/1/09/514/011 20090421; UK EU/1/09/514/012 20090421 |
| 2435025 | LUC00124 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220 |
| 1591446 | 122022000002 | Germany | ⤷ Try a Trial | PRODUCT NAME: RELUGOLIX ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1565 20210716 |
| 2435024 | 2190014-7 | Sweden | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF FORMOTEROL INCLUDING ANY PHARMACEUUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, GLYCOPYRROLATE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, AND BUDESONIDE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALT, ESTERS ORSOLVATES THEREOF; REG. NO/DATE: EU/1/20/1498 20201210 |
| 1591446 | SPC/GB21/065 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: RELUGOLIX OR A SALT THEREOF; REGISTERED: UK EU/1/21/1565(NI) 20210720; UK FURTHER MA ON IPSUM 20210720 |
| 0751129 | 09C0040 | France | ⤷ Try a Trial | PRODUCT NAME: ESLICARBAZEPINE ACETATE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/514/001 DU 20090421; REGISTRATION NO/DATE AT EEC: EU/1/09/514/001 DU 20090421 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
